Alzheimer's disease is one of the world’s most prevalent brain disorders, being extremely difficult to treat. Alzheimer's ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

The scans are also expensive and not available at all hospitals. More sensitive ways to detect amyloid and tau, another protein related to the disease, are possible by analyzing spinal fluid ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

Those findings were integrated with data collected from the participants on cerebrospinal fluid and brain-scan biomarkers of amyloid- β and tau protein, cognitive function, age, sex and Alzheimer ...

A recent study revealed that an experimental blood test for Alzheimer’s disease not only can help in accurate diagnosis but ...

Current biomarkers of cognitive impairment in individuals with Alzheimer’s disease perform poorly. Now, a stronger predictor ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

The researchers have been testing amyloid-removing therapies ... with sticky plaques made from beta amyloid proteins and toxic tangles made of a protein called tau. They theorized that removing ...